Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: health insurance

Mark Cuban: Mixing Up the Pharmaceutical Landscape

Catherine Kolonko  |  April 7, 2023

The Mark Cuban Cost Plus Drug Co. (CPD) launched in January 2022 to distribute and home deliver prescribed generic medications to consumers. The Texas-based business seeks to reduce the prices of generic drugs by leapfrogging financial negotiators and going straight to drug companies for supply, according to a news release.1 “It’s crazy that medications are…

Filed under:Drug Updates Tagged with:pharmacy benefit managersprescription drug prices

Zoledronic Acid vs. Oral Bisphosphonates: Osteoporosis Treatments & the Risk of Developing Osteonecrosis of the Jaw

Michele B. Kaufman, PharmD, BCGP  |  December 12, 2022

A study from Amigues et al. found that bisphosphonate-associated osteonecrosis of the jaw is rare in patients with osteoporosis and may occur more often in patients treated with injectable zoledronic acid than in those treated with the oral bisphosphonates.

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesEULARONJosteonecrosis of the jawOsteoporosiszoledronic acid

Speak Out Rheum: To Prescribe Is Humane (Unless You’re In Texas)

Raymond Scalettar, MD, DSc  |  November 7, 2022

You are a rheumatologist in Texas. You are very well trained. Your mentors included some of the leaders in rheumatology, and you are respected by your colleagues and your patients. You know the devastation of untreated rheumatoid arthritis and lupus. A young woman with recent onset of systemic lupus erythematosus is your new patient. You…

Filed under:EthicsLegal UpdatesOpinionProfessional TopicsSpeak Out Rheum Tagged with:abortionMethotrexatepregnancySpeak Out Rheumatology

ACR Proposes New ICD-10 Code to Capture ‘Pre-RA’

From the College  |  October 7, 2022

On Sept. 13, the ACR and Kevin D. Deane, MD, PhD, presented a proposal to create a new clinical code to recognize a condition in which an individual may exhibit rheumatoid arthritis-related autoantibodies without clinical presentation.

Filed under:Billing/CodingFrom the College Tagged with:CodingICD-10 code change requestpre-rheumatoid arthritisRheumatoid Arthritis (RA)

2022 RDAM Report Card

Rheumatic Disease Report Card 2022 Released: No A’s Given Overall; Oklahoma Ranks Most Improved

Vanessa Caceres  |  September 13, 2022

The 2022 Rheumatic Disease Report Card found that many states can improve access to care, affordability & activity for their residents living with rheumatic diseases.

Filed under:American College of RheumatologyFrom the College Tagged with:RDAMReport CardRheumatic Disease Awareness Month

How the U.S. Will Set Up New Medicare Drug Price Talks

Ahmed Aboulenein  |  September 6, 2022

WASHINGTON—The U.S. government will soon begin hiring experts and collecting the data needed to launch direct negotiations over prescription drug prices for older and disabled people, a top Biden administration official told Reuters. President Joe Biden last week signed into law the Inflation Reduction Act, introducing new policies to tackle climate change, taxes and the…

Filed under:Drug UpdatesLegislation & Advocacy Tagged with:Centers for Medicare & Medicaid Services (CMS)drug pricingInflation Reduction ActpolicyU.S. Centers for Medicare and Medicaid Services (CMS)

Dermatologist, Rheumatologist Discuss Refractory Cutaneous Lupus Case

Richard D. Sontheimer, MD, & Samantha C. Shapiro, MD  |  September 5, 2022

As a dermatologist/internist with a career-long subspecialty interest in the cutaneous manifestations of the rheumatic diseases, I found the case of refractory acute cutaneous lupus by Samantha C. Shapiro, MD, in the June 2022 issue of The Rheumatologist intriguing in several ways, and I felt my perspectives on this case might provide additional educational value…

Filed under:ConditionsOpinionSpeak Out RheumSystemic Lupus Erythematosus Tagged with:case reportcutaneous lupus erythematosus (CLE)Dermatologydiagnostic imagingimage caseimage case reportletter to the editor

Florida Law Puts Drug Pricing by Pharmacy Benefit Managers Under a Microscope Once Again

Catherine Kolonko  |  August 8, 2022

As of July 1, a Florida bill increases oversight of pharmacy benefit managers and offers some protection for pharmacies. However, the legislation has limited effects on patients and providers, highlighting the need for additional reform.

Filed under:Legislation & Advocacy Tagged with:Floridapharmacy benefit managers (PBMs)state legislation

Zenobillis / shutterstock.com

Rheumatologists Share Lessons Learned in the Wake of Hurricane Ida

Susan Bernstein  |  July 13, 2022

Hurricane Ida intensified in the last two weeks of August 2021, battering the Cayman Islands and Cuba before hitting the Louisiana coast as a Category 4 storm just before Labor Day weekend.1 At landfall, Ida blasted southern Louisiana with maximum sustained winds of 150 knots, then turned in a north-northwestern direction to hit the New…

Filed under:EMRsFacilityPractice Support Tagged with:Disaster preparationNatural disaster

ACR-FDA Summit Focuses on Study Design, Safety Considerations

Vanessa Caceres  |  June 21, 2022

Safety considerations and data sources are crucial to consider when designing studies for rheumatology treatments, according to presenters at the 2022 ACR-FDA Summit.

Filed under:Meeting Reports Tagged with:ACR-FDA Summitclinical trialsstudy design

  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 116
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences